Lung Based Engineered Micro-Pancreas Sustains Human Beta Cell Survival and Functionality.
Lung Based Engineered Micro-Pancreas Sustains Human Beta Cell Survival and Functionality.
复制标题
基于肺的工程微胰腺维持人类β细胞的存活和功能。
DOI：
10.1055/a-1041-3305
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Goldman O
中科院分区：
文献类型：
--
作者：
Goldman O
整个世界都受到糖尿病发病率急剧增加的影响。今天，1型和2型糖尿病的病因被认为是围绕β细胞功能障碍，β细胞是身体的胰岛素产生细胞。在制药行业，用于糖尿病治疗的新药的评估主要是使用细胞系或啮齿动物胰岛进行的，并且仅取决于静态胰岛素分泌的评估。然而，细胞系或啮齿动物胰岛的使用限制了人类胰岛细胞相似性的缺乏，导致关于新开发药物的临床潜力的预测值的限制。为了克服这个问题，我们开发了一种工程微胰腺作为药物发现的独特平台。工程化微胰腺由（i）器官衍生的微支架，特别是脱细胞猪肺衍生的微支架和（ii）接种在其上的尸体胰岛组成。工程微胰腺在体外保持活力并维持胰岛素分泌长达三个月。胰岛素的量与新鲜分离的人胰岛分泌的量相当，因此具有实时和代谢生理学模拟药物筛选的潜力。
The whole world has been affected by a dramatically increasing prevalence of diabetes. Today, the etiology of both type 1 and type 2 diabetes is thought to revolve around the dysfunction of β-cells, the insulin producing cells of the body. Within the pharmaceutical industry, the evaluation of new drugs for diabetes treatment is mostly done using cell lines or rodent islets and depends solely on the assessment of static insulin secretion. However, the use of cell lines or rodent islets is limiting lack of similarity of the human islet cells, leading to a constrain of the predictive value regarding the clinical potential of newly developed drugs. To overcome this issue, we developed an Engineered Micro-Pancreas as a unique platform for drug discovery. The Engineered Micro Pancreas is composed of (i) an organ-derived micro-scaffold, specifically a decellularized porcine lung-derived micro-scaffold and (ii) cadaveric islets seeded thereon. The Engineered Micro Pancreas remained viable and maintained insulin secretion in vitro for up to three months. The quantities of insulin were comparable to those secreted by freshly isolated human islets and therefore hold the potential for real-time and metabolic physiology mimicking drug screening.